A $250M target fund providing blended exposure across selective innovation, enabling services, healthcare AI and cash-flow acquisitions. Allocations, economics and underwriting detail are provided in the data room.
Milestone-driven equity in platform biology, anchored by an investigational program and a staged pipeline of additional technologies pursuing defined proof milestones, licensing and strategic exits.
Capital is staged to verifiable proof points. The anchor is an investigational regenerative-medicine program (BioViva Neuro — investigational and not FDA approved), paired with additional innovation companies subject to diligence and defined evidence milestones. Value depends on scientific, regulatory, CMC and controlled-evidence outcomes.
Operating businesses and capabilities that combine standalone economic potential with manufacturing, access, evidence, AI and operating utility that can support portfolio execution.
Portfolio role
Process development, quality, manufacturing and research biofabrication.
Potential economics
Third-party services, equipment, consumables, licensing and strategic asset value.
Portfolio role
Provider access, structured evidence workflows, training, licensing and commercial execution.
Potential economics
Service fees, licensing, royalties and JV economics where agreements provide.
Portfolio role
Equity investments and AI capabilities that support research and operating workflows across portfolio companies.
Potential economics
Commercial adoption and software/IP value, with proceeds through actual equity or rights.
Portfolio role
Operating ownership in established healthcare and longevity businesses.
Potential economics
Cash flow after business needs and debt service, debt paydown, recapitalization or sale.
Portfolio support may improve execution but does not guarantee revenue, clinical success, lower cost or realization. Unless expressly identified as closed, opportunities are prospective.
Company value, Aether's economic interest, realized fund cash and LP distributions are distinct steps and should not be treated as interchangeable.
Illustrative only. Realizations and distributions are not assured. Repaid or recycled principal is not additional profit. Modeled returns and fund terms are provided in the data room under NDA.
Important information. Confidential discussion material for accredited investors only; not an offer or solicitation. Company names, allocations, valuations, timelines and economics are forward-looking, subject to diligence and definitive documents, and may change. Investigational programs are not FDA approved. Investments are illiquid and may result in total loss of capital.
